China dominates global licensing deal value as US biotech M&A surges
Start here
Global dealmaking patterns shifted sharply in 2026. China now accounts for 58% of global licensing deal value, up dramatically as the U.S. share has fallen from 56% in 2024 to 26%. Meanwhile, U.S. biotech M&A is booming, with $173 billion in total deal value through the third quarter — already exceeding the $151 billion recorded for all of 2025. Across 89 M&A deals, U.S.-headquartered companies account for 91% of deal value, while Chinese companies hold just 1%. The data, reported in October 2026, points to a bifurcated landscape: U.S. firms consolidating through acquisition while Chinese assets lead the world in licensing activity.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- BioSpacePickChina’s licensing deals soar as US biotechs enjoy a bumper M&A year
China accounted for 58% of global licensing deal value in 2026, while the U.S. fell from 56% in 2024 to 26%; U.S. biotech M&A totaled $173 billion. That M&A total through the third quarter already exceeded the $151 billion for all of 2025; across 89 deals, U.S.-headquartered companies captured 91% of deal value, compared with 1% for Chinese companies.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 13:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.